Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioCryst Pharmaceuticals (NAS:BCRX) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
BioCryst Pharmaceuticals Forward PE Ratio Related Terms
BioCryst Pharmaceuticals Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioCryst Pharmaceuticals Forward PE Ratio Chart
BioCryst Pharmaceuticals Annual Data
Trend
2025-12
Forward PE Ratio
21.99
BioCryst Pharmaceuticals Quarterly Data
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
77.28
13.92
21.99
31.73
BCRX vs SUPN, PBH, AMLX: Forward PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioCryst Pharmaceuticals Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where BioCryst Pharmaceuticals's Forward PE Ratio falls into.
BioCryst Pharmaceuticals Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
BioCryst Pharmaceuticals (BCRX) has a Forward PE Ratio of 29.93 as of Jul. 16, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on BioCryst Pharmaceuticals and its competitors. According to the industry distribution chart, BioCryst Pharmaceuticals ranks #307 out of 409 companies in the Drug Manufacturers industry, placing it in the top 75.1%.
Is BioCryst Pharmaceuticals' Forward PE Ratio too high?
BioCryst Pharmaceuticals' current Forward PE Ratio is 29.93. The Drug Manufacturers industry median Forward PE Ratio is 17.52. BioCryst Pharmaceuticals' value of 29.93 is 70.8% above this industry median. Based on the distribution chart, BioCryst Pharmaceuticals ranks #307 out of 409 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioCryst Pharmaceuticals has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioCryst Pharmaceuticals' Forward PE Ratio compare to SUPN and PBH?
According to the Drug Manufacturers industry distribution chart, BioCryst Pharmaceuticals ranks #307 out of 409 companies for Forward PE Ratio. This places BioCryst Pharmaceuticals in the lower half of its industry. The industry median Forward PE Ratio is 17.52. BioCryst Pharmaceuticals' value of 29.93 is 70.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.52, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioCryst Pharmaceuticals's current Forward PE Ratio of 29.93 is 70.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on BioCryst Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioCryst Pharmaceuticals's current Forward PE Ratio is 29.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCryst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals (BCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $12.43, compared to a current price of $9.15 — trading 26.4% below its estimated fair value. The current Forward PE Ratio is 29.93 and 70.8% above the Drug Manufacturers industry median of 17.52. BioCryst Pharmaceuticals' overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For BioCryst Pharmaceuticals (BCRX), the current Forward PE Ratio is 29.93 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioCryst Pharmaceuticals (BCRX) Overvalued in 2026?
Based on GuruFocus' analysis, BioCryst Pharmaceuticals stock appears to be undervalued.
The current stock price of $9.15 is trading 26.4% below its estimated GF Value™ of $12.43.
GuruFocus considers BioCryst Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for BCRX:
Forward PE Ratio: 29.93
GF Value™: $12.43 vs. price of $9.15 (26.4% below fair value)
Industry Position: 70.8% above the Drug Manufacturers median (#307 of 409)
No single metric tells the full story. See the BCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
67GF Score
Get the complete analysis for BCRX
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCRX has been successfully added to your 
